🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the battle against superbug strains of the infection, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with data suggesting over 82 million new cases per year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the American regulatory agency in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This authorization marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The trial involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians directly involved have expressed positive views. Having a single-dose, oral treatment like this is described as a "critical tool" for managing the epidemic. This is considered essential to reduce the burden of the infection for individuals and to stop the proliferation of untreatable gonorrhoea globally.